Relative impact of COPD and comorbidities on generic health-related quality of life: a pooled analysis of the COSYCONET patient cohort and control subjects from the KORA and SHIP studies

Margarethe E Wacker, Rudolf A Jörres, Annika Karch, Armin Koch, Joachim Heinrich, Stefan Karrasch, Holger Schulz, Annette Peters, Sven Gläser, Ralf Ewert, Sebastian E Baumeister, Claus Vogelmeier, Reiner Leidl, Rolf Holle, COSYCONET study group, Margarethe E Wacker, Rudolf A Jörres, Annika Karch, Armin Koch, Joachim Heinrich, Stefan Karrasch, Holger Schulz, Annette Peters, Sven Gläser, Ralf Ewert, Sebastian E Baumeister, Claus Vogelmeier, Reiner Leidl, Rolf Holle, COSYCONET study group

Abstract

Background: Health-related quality of life (HRQL) is an important patient-reported outcome measure used to describe the burden of chronic obstructive pulmonary disease (COPD) which is often accompanied by comorbid conditions.

Methods: Data from 2275 participants in the COPD cohort COSYCONET and from 4505 lung-healthy control subjects from the population-based KORA and SHIP studies were pooled. Main outcomes were the five dimensions of the generic EQ-5D-3 L questionnaire and two EQ-5D index scores using a tariff based on valuations from the general population and an experience-based tariff. The association of COPD in GOLD grades 1-4 and of several comorbid conditions with the EQ-5D index scores was quantified by multiple linear regression models while adjusting for age, sex, education, body mass index (BMI), and smoking status.

Results: For all dimensions of the EQ-5D, the proportion of participants reporting problems was higher in the COPD group than in control subjects. COPD was associated with significant reductions in the EQ-5D index scores (-0.05 points for COPD grades 1/2, -0.09 for COPD grade 3, -0.18 for COPD grade 4 according to the preference-based utility tariff, all p < 0.0001). Adjusted mean index scores were 0.89 in control subjects and 0.85, 0.84, 0.81, and 0.72 in COPD grades 1-4 according to the preference-based utility tariff and 0.76, 0.71, 0.68, 0.64, and 0.58 for control subjects and COPD grades 1-4 for the experience-based tariff respectively. Comorbidities had additive negative effects on the index scores; the effect sizes for comorbidities were comparable to or smaller than the effects of COPD grade 3. No statistically significant interactions between COPD and comorbidities were observed. Score differences between COPD patients and control subjects were most pronounced in younger age groups.

Conclusions: Compared with control subjects, the considerable reduction of HRQL in patients with COPD was mainly due to respiratory limitations, but observed comorbidities added linearly to this effect. Younger COPD patients showed a greater loss of HRQL and may therefore be in specific need of comprehensive disease management.

Trial registration: NCT01245933.

Keywords: COPD; Cohort study; Comorbidities; Health-related quality of life; Utilities.

Figures

Fig. 1
Fig. 1
Study flow chart
Fig. 2
Fig. 2
EQ-5D dimensions: % of participants reporting problems (unadjusted)
Fig. 3
Fig. 3
Adjusted mean EQ-5D index scores. Models adjusted for age, sex, and education
Fig. 4
Fig. 4
Adjusted EQ-5D index score stratified by age group. Models adjusted for age, sex, and education

References

    1. World Health Organization. The top 10 causes of death, Fact sheet N°310. . Accessed 27 Mar 2016.
    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (Update 2015). . Accessed 17 Mar 2016.
    1. Justine M, Tahirah F, Mohan V. Health-related quality of life, lung function and dyspnea rating in COPD patients. Monaldi Arch Chest Dis. 2013;79:116–20. doi: 10.4081/monaldi.2013.5209.
    1. Rubinsztajn R, Przybylowski T, Maskey-Warzechowska M, Karwat K, Chazan R. Exacerbations of Chronic Obstructive Pulmonary Disease and Quality of Life of Patients. Adv Exp Med Biol. 2016;884:69–74. doi: 10.1007/5584_2015_178.
    1. Menn P, Weber N, Holle R. Health-related quality of life in patients with severe COPD hospitalized for exacerbations - comparing EQ-5D, SF-12 and SGRQ. Health Qual Life Outcomes. 2010;8:39. doi: 10.1186/1477-7525-8-39.
    1. Miravitlles M, Huerta A, Valle M, Garcia-Sidro P, Forne C, Crespo C, Lopez-Campos JL. Clinical variables impacting on the estimation of utilities in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2015;10:367–77. doi: 10.2147/COPD.S76397.
    1. Miravitlles M, Ferrer M, Pont A, Zalacain R, Alvarez-Sala JL, Masa F, Verea H, Murio C, Ros F, Vidal R. Effect of exacerbations on quality of life in patients with chronic obstructive pulmonary disease: a 2 year follow up study. Thorax. 2004;59:387–95. doi: 10.1136/thx.2003.008730.
    1. Huber MB, Wacker ME, Vogelmeier CF, Leidl R. Comorbid Influences on Generic Health-Related Quality of Life in COPD: A Systematic Review. PLoS ONE. 2015;10:e0132670. doi: 10.1371/journal.pone.0132670.
    1. Koskela J, Kilpelainen M, Kupiainen H, Mazur W, Sintonen H, Boezen M, Lindqvist A, Postma D, Laitinen T. Co-morbidities are the key nominators of the health related quality of life in mild and moderate COPD. BMC Pulm Med. 2014;14:102. doi: 10.1186/1471-2466-14-102.
    1. Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and burden of COPD: a population based case-control study. PLoS ONE. 2013;8:e63285. doi: 10.1371/journal.pone.0063285.
    1. Decramer M, Rennard S, Troosters T, Mapel DW, Giardino N, Mannino D, Wouters E, Sethi S, Cooper CB. COPD as a lung disease with systemic consequences--clinical impact, mechanisms, and potential for early intervention. COPD. 2008;5:235–56. doi: 10.1080/15412550802237531.
    1. Rutten-van Molken MP, Oostenbrink JB, Tashkin DP, Burkhart D, Monz BU. Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest. 2006;130:1117–28. doi: 10.1378/chest.130.4.1117.
    1. Kwon HY, Kim E. Factors contributing to quality of life in COPD patients in South Korea. Int J Chron Obstruct Pulmon Dis. 2016;11:103–9. doi: 10.2147/COPD.S90566.
    1. Hong JY, Kim SY, Chung KS, Kim EY, Jung JY, Park MS, Kang YA, Kim SK, Chang J, Kim YS. Factors associated with the quality of life of Korean COPD patients as measured by the EQ-5D. Qual Life Res. 2015;24:2549–58. doi: 10.1007/s11136-015-0979-6.
    1. Jones PW. Health status measurement. In: Kolb M, Vogelmeier CF, editors. Outcomes in Clinical Trials. Lausanne: European Respiratory Society; 2013. pp. 96–104.
    1. Knies S, Evers SM, Candel MJ, Severens JL, Ament AJ. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics. 2009;27:767–79. doi: 10.2165/11314120-000000000-00000.
    1. Karch A, Vogelmeier C, Welte T, Bals R, Kauczor HU, Biederer J, Heinrich J, Schulz H, Gläser S, Holle R, et al. The German COPD cohort COSYCONET: Aims, methods and descriptive analysis of the study population at baseline. Respir Med. 2016;114:27–37. doi: 10.1016/j.rmed.2016.03.008.
    1. Jorres RA, Welte T, Bals R, Koch A, Schnoor M, Vogelmeier C. Systemic manifestations and comorbidities in patients with chronic obstructive pulmonary disease (COPD) and their effect on clinical state and course of the disease--an overview of the cohort study COSYCONET. Dtsch Med Wochenschr. 2010;135:446–9. doi: 10.1055/s-0030-1249185.
    1. Holle R, Happich M, Lowel H, Wichmann HE. KORA--a research platform for population based health research. Gesundheitswesen. 2005;67(Suppl 1):S19–25. doi: 10.1055/s-2005-858235.
    1. Peters A, Doring A, Ladwig KH, Meisinger C, Linkohr B, Autenrieth C, Baumeister SE, Behr J, Bergner A, Bickel H, et al. Multimorbidity and successful aging: the population-based KORA-Age study. Z Gerontol Geriatr. 2011;44 Suppl 2:41–54. doi: 10.1007/s00391-011-0245-7.
    1. Volzke H, Alte D, Schmidt CO, Radke D, Lorbeer R, Friedrich N, Aumann N, Lau K, Piontek M, Born G, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40:294–307. doi: 10.1093/ije/dyp394.
    1. Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, Enright PL, Hankinson JL, Ip MSM, Zheng J, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40:1324–43. doi: 10.1183/09031936.00080312.
    1. Dolan P. Output measures and valuation of health. In: Drummond M, Alistair M, editors. Economic evaluations in health care. Oxford: Oxford University Press; 2010. pp. 46–67.
    1. Greiner W, Claes C, Busschbach JJ, von der Schulenburg JM. Validating the EQ-5D with time trade off for the German population. Eur J Health Econ. 2005;6:124–30. doi: 10.1007/s10198-004-0264-z.
    1. Leidl R, Reitmeir P. A value set for the EQ-5D based on experienced health states: development and testing for the German population. Pharmacoeconomics. 2011;29:521–34. doi: 10.2165/11538380-000000000-00000.
    1. Vogl M, Wenig CM, Leidl R, Pokhrel S. Smoking and health-related quality of life in English general population: implications for economic evaluations. BMC Public Health. 2012;12:203. doi: 10.1186/1471-2458-12-203.
    1. Soltoft F, Hammer M, Kragh N. The association of body mass index and health-related quality of life in the general population: data from the 2003 Health Survey of England. Qual Life Res. 2009;18:1293–9. doi: 10.1007/s11136-009-9541-8.
    1. Hunger M, Baumert J, Holle R. Analysis of SF-6D index data: is beta regression appropriate? Value Health. 2011;14:759–67. doi: 10.1016/j.jval.2010.12.009.
    1. Martinez CH, Diaz AA, Parulekar AD, Rennard SI, Kanner RE, Hansel NN, Couper D, Holm KE, Hoth KF, Curtis JL, et al. Age-Related Differences in Health-Related Quality of Life in COPD: An Analysis of the COPDGene and SPIROMICS Cohorts. Chest. 2016;149(4):927–35. doi: 10.1016/j.chest.2015.11.025.
    1. Nici L, ZuWallack R. An official American Thoracic Society workshop report: the Integrated Care of The COPD Patient. Proc Am Thorac Soc. 2012;9:9–18. doi: 10.1513/pats.201201-014ST.
    1. Szende A, Oppe M, Devlin N. EQ-5D Value Sets: Inventory, Comparative Review and User Guide. Dordrecht: Springer Netherlands; 2007.
    1. Weldam SWM, Schuurmans MJ, Liu R, Lammers J-WJ. Evaluation of Quality of Life instruments for use in COPD care and research: A systematic review. Int J Nurs Stud. 2013;50:688–707. doi: 10.1016/j.ijnurstu.2012.07.017.
    1. Petrillo J, van Nooten F, Jones P, Rutten-van MM. Utility estimation in chronic obstructive pulmonary disease: a preference for change? Pharmacoeconomics. 2011;29:917–32. doi: 10.2165/11589280-000000000-00000.
    1. Wacker ME, Jörres RA, Karch A, Wilke S, Heinrich J, Karrasch S, Koch A, Schulz H, Watz H, Leidl R, Vogelmeier C, Holle R, COSYCONET-Consortium Assessing health-related quality of life in COPD: comparing generic and disease-specific instruments with focus on comorbidities. BMC Pulm Med. 2016;16(1):70. doi: 10.1186/s12890-016-0238-9.
    1. Luo N, Johnson J, Coons SJ. Using instrument-defined health state transitions to estimate minimally important differences for four preference-based health-related quality of life instruments. Med Care. 2010;48:365–71. doi: 10.1097/MLR.0b013e3181c162a2.
    1. Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res. 2005;14:1523–32. doi: 10.1007/s11136-004-7713-0.
    1. Stahl E, Lindberg A, Jansson S-A, Ronmark E, Svensson K, Andersson F, Lofdahl C-G, Lundback B. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes. 2005;3:56. doi: 10.1186/1477-7525-3-56.
    1. Jones PW, Brusselle G, Dal Negro RW, Ferrer M, Kardos P, Levy ML, Perez T, Soler-Cataluna JJ, van der Molen T, Adamek L, Banik N. Health-related quality of life in patients by COPD severity within primary care in Europe. Respir Med. 2011;105:57–66. doi: 10.1016/j.rmed.2010.09.004.
    1. Miravitlles M, Huerta A, Fernandez-Villar JA, Alcazar B, Villa G, Forne C, Cuesta M, Crespo C, Garcia-Rio F. Generic utilities in chronic obstructive pulmonary disease patients stratified according to different staging systems. Health Qual Life Outcomes. 2014;12:120. doi: 10.1186/s12955-014-0120-5.
    1. Pickard AS, Wilke C, Jung E, Patel S, Stavem K, Lee TA. Use of a preference-based measure of health (EQ-5D) in COPD and asthma. Respir Med. 2008;102:519–36. doi: 10.1016/j.rmed.2007.11.016.
    1. Einarson TR, Bereza BG, Nielsen TA, Hemels ME. Utilities for asthma and COPD according to category of severity: a comprehensive literature review. J Med Econ. 2015;18:550–63. doi: 10.3111/13696998.2015.1025793.
    1. Leidl R, Schweikert B, Hahmann H, Steinacker JM, Reitmeir P. Assessing quality of life in a clinical study on heart rehabilitation: how well do value sets based on given or experienced health states reflect patients’ valuations? Health Qual Life Outcomes. 2016;48:1.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться